Internal Reference Number: FOI_6968
Date Request Received: 17/01/2023 00:00:00
Date Request Replied To: 07/02/2023 00:00:00
This response was sent via: By Email
Request Summary: Usage of biologic and biosimilar products within Rheumatology.
Request Category: Companies
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara | |
| Answer To Question 1: We have treated 977 patients in the last 3 months with the stated list of drugs split as follows: Abatacept 42 Adalimumab Biosimilars 289 Humira 29 Apremilast 6 Baricitinib 70 Certolizumab 39 Enbrel 11 Etanercept Biosimilars 129 Filgotinib 30 Golimumab 23 Infliximab Biosimilars 21 Remicade 8 Ixekizumab 35 Mabthera 7 Rituximab Biosimilars 92 Sarilumab <5 Secukinumab 20 Tocilizumab 50 Tofacitinib 30 Upadacitinib 42 Ustekinumab <5 | |
| Question Number 2: Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs. • Adalimumab [Humira] • Adalimumab Biosimilars • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Golimumab [Simponi] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Secukinumab [Cosentyx] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] | |
| Answer To Question 2: We have treated 150 AxSpa patients in the last 3 months with the stated list of drugs, split as follows: Humira 12 Adalimumab Biosimilars 57 Certolizumab 13 Enbrel <5 Etanercept Biosimilars 29 Golimumab 10 Infliximab Biosimilars 12 Remicade <5 Ixekizumab <5 Secukinumab 12 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
